Vol. 60 No. 2 (2021): Acta Oncologica

Articles

• Approval of new drugs in oncology – a changing pattern

  Hans Hagberg

  141-142

  Published: 2021-02-01

  • PDF

• Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency

  Ken Hatogai, Yuka Kato, Chikara Hirase

  143-148

  Published: 2021-02-01

  • PDF

• Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy

  Åsa Kristina Öjlert, Daniel Nebdal, Marius Lund-Iversen, Renée Åstrøm Ellefsen, Odd Terje Brustugun, Jon Michael Gran, Ann Rita Halvorsen, Åslaug Helland

  149-156

  Published: 2021-02-01

  • PDF

• Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

  Anne Sofie Brems-Eskildsen, Søren Linnet, Hella Danø, Adam Luczak, Peter Michael Vestlev, Erik Hugger Jakobsen, Jeppe Neimann, Charlotte Buch Jensen, Trine Dongsgaard, Sven Tyge Langkjer

  157-164

  Published: 2021-02-01

  • PDF

• Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990–2014

  Emma K. Rousi, Ilkka O. Koskivuo, Susanna M. Juteau, Lauri A. I. Talve, Micaela M. Hernberg, Pia P. Vihinen, Veli-Matti Kähäri

  165-172

  Published: 2021-02-01

  • PDF

• The impact of comorbidities on survival in oral cancer patients: a population-based, case-control study

  Mustafa Ghanizada, Kathrine Kronberg Jakobsen, Jakob Schmidt Jensen, Irene Wessel, Jesper Filtenborg Tvedskov, Christian Grønhøj, Christian von Buchwald

  173-179

  Published: 2021-02-01

  • PDF

• Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort

  H. Rumpold, P. Kirchweger, D. Niedersüß-Beke, D. Falch, H. Wundsam, S. Metz-Gercek, G. Piringer, J. Thaler

  180-186

  Published: 2021-02-01

  • PDF

• Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort

  Irina Tsibulak, Verena Wieser, Hannah Welponer, Katharina Leitner, Hubert Hackl, Christian Marth, Heidelinde Fiegl, Alain G. Zeimet

  187-190

  Published: 2021-02-01

  • PDF

• Transparency in reporting of phase 3 cancer clinical trial results

  Roshal R. Patel, Vivek Verma, Clifton D. Fuller, Zachary R. McCaw, Ethan B. Ludmir

  191-194

  Published: 2021-02-01

  • PDF

• Hepatotoxicity associated with ribociclib among breast cancer patients

  Stefania Finnsdottir, Asgerdur Sverrisdottir, Einar S. Björnsson

  195-198

  Published: 2021-02-01

  • PDF

• Robust treatment planning of dose painting for prostate cancer based on ADC-to-Gleason score mappings – what is the potential to increase the tumor control probability?

  Eric Grönlund, Erik Almhagen, Silvia Johansson, Erik Traneus, Tufve Nyholm, Camilla Thellenberg, Anders Ahnesjö

  199-206

  Published: 2021-02-01

  • PDF

• Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience

  Katharina Eibenberger, Roman Dunavoelgyi, Andreas Gleiss, Aleksandra Sedova, Dietmar Georg, Richard Poetter, Karin Dieckmann, Martin Zehetmayer

  207-214

  Published: 2021-02-01

  • PDF

• Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy

  Luca Nicosia, Gianluisa Sicignano, Michele Rigo, Vanessa Figlia, Francesco Cuccia, Antonio De Simone, Niccolò Giaj-Levra, Rosario Mazzola, Stefania Naccarato, Francesco Ricchetti, Claudio Vitale, Ruggero Ruggieri, Filippo Alongi

  215-221

  Published: 2021-02-01

  • PDF

• Effect of breathing motion on robustness of proton therapy plans for left-sided breast cancer patients with indication for locoregional irradiation

  L. Klaassen, A. L. Petoukhova, S. J. M. Habraken, J. Jacobs, M. G. A. Sattler, K. Verhoeven, Y. L. B. Klaver

  222-228

  Published: 2021-02-01

  • PDF

• Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention

  H. M. Patrick, L. Souhami, J. Kildea

  229-236

  Published: 2021-02-01

  • PDF

• Clinical iterative model development improves knowledge-based plan quality for high-risk prostate cancer with four integrated dose levels

  Johanna Austrheim Hundvin, Kristine Fjellanger, Helge Egil Seime Pettersen, Britt Nygaard, Kari Revheim, Turid Husevåg Sulen, Christian Ekanger, Liv Bolstad Hysing

  237-244

  Published: 2021-02-01

  • PDF

• High-dose proton therapy and tomotherapy for the treatment of sacral chordoma: a retrospective monocentric study

  Arnaud Beddok, Caroline Saint-Martin, Hamid Mammar, Loïc Feuvret, Sylvie Helfre, Stéphanie Bolle, Sebastien Froelich, Farid Goudjil, Sofia Zefkili, Malika Amessis, Dominique Peurien, Sophie Cornet, Rémi Dendale, Claire Alapetite, Valentin Calugaru

  245-251

  Published: 2021-02-01

  • PDF

• Incorporation of the LETd-weighted biological dose in the evaluation of breast intensity-modulated proton therapy plans

  Chunbo Liu, Dandan Zheng, Julie A. Bradley, Raymond B. Mailhot Vega, Yawei Zhang, Daniel J. Indelicato, Nancy Mendenhall, Xiaoying Liang

  252-259

  Published: 2021-02-01

  • PDF

• Simulated daily plan adaptation for magnetic resonance-guided liver stereotactic body radiotherapy

  Edward Taylor, Jelena Lukovic, Michael Velec, Andrea Shessel, Teodor Stanescu, Laura Dawson, Daniel Létourneau, Patricia Lindsay

  260-266

  Published: 2021-02-01

  • PDF

• Variation in relative biological effectiveness for cognitive structures in proton therapy of pediatric brain tumors

  Ole Marius Otterlei, Daniel J. Indelicato, Laura Toussaint, Kristian S. Ytre-Hauge, Sara Pilskog, Lars Fredrik Fjaera, Eivind Rørvik, Helge Egil S. Pettersen, Ludvig P. Muren, Yasmin Lassen-Ramshad, Marcos Di Pinto, Camilla H. Stokkevåg

  267-274

  Published: 2021-02-01

  • PDF